Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable HER2-Positive Breast Carcinoma”

94 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 94 results

Not applicableLooking for participantsNCT05573893
What this trial is testing

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Who this might be right for
Breast NeoplasmsBreast CancerNeoplasm Metastasis
AstraZeneca 800
Large-scale testing (Phase 3)Active Not RecruitingNCT03529110
What this trial is testing

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Who this might be right for
Breast Cancer
Daiichi Sankyo 524
Testing effectiveness (Phase 2)Ended earlyNCT05583110
What this trial is testing

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
Spanish Breast Cancer Research Group 13
Large-scale testing (Phase 3)Active Not RecruitingNCT04639986
What this trial is testing

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 331
Testing effectiveness (Phase 2)Study completedNCT04420598
What this trial is testing

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Who this might be right for
Advanced Breast CancerHER2-positive Breast CancerBrain Metastases+1 more
MedSIR 41
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Early research (Phase 1)WithdrawnNCT06590558
What this trial is testing

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Post-approval studies (Phase 4)Looking for participantsNCT06429761
What this trial is testing

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Who this might be right for
BREAST CANCER
AstraZeneca 100
Testing effectiveness (Phase 2)Looking for participantsNCT06686394
What this trial is testing

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 81
Post-approval studies (Phase 4)Study completedNCT02658734
What this trial is testing

Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Who this might be right for
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche 70
Not applicableWithdrawnNCT02616224
What this trial is testing

Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Large-scale testing (Phase 3)Active Not RecruitingNCT03975647
What this trial is testing

Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 466
Not applicableLooking for participantsNCT06676436
What this trial is testing

Observational Study on the Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Cancer
AstraZeneca 200
Large-scale testing (Phase 3)Active Not RecruitingNCT04732598
What this trial is testing

A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Japanese Foundation for Cancer Research 280
Testing effectiveness (Phase 2)Active Not RecruitingNCT04721977
What this trial is testing

Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Who this might be right for
Breast Cancer
Pfizer 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 135
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Load More Results